GGrantIndex
← Leaderboards

Nancy E Thomas

University Of North Carolina Chapel Hill

Google Scholar ↗PubMed ↗ORCID ↗
$10,693,117
Attributed
$14,530,852
Total exposure
9
Grants
8
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3.7M · FY2005–24
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24

Funding mix

By agency

NIH$24,609,486 · 10

By mechanism

P01$12,387,065 · 3
R01$9,938,716 · 2
R33$979,154 · 1
K07$650,290 · 1
R21$356,261 · 1
R03$298,000 · 2

Top collaborators

Most similar at University Of North Carolina Chapel Hill

Same institution · by research overlap

Others in their field

Top investigators on “Melanoma”

Research focus

MelanomaTumorNeoplasm MetastasisGenesDiagnosisStagingMalignant NeoplasmsMolecularMutationProgramsBaseSomatic MutationEpidemiologyBraf GeneCharacteristicsHeterogeneityPathologicPrognosticInternationalAmerican Joint Committee On CancerTissuesDiagnostic Neoplasm StagingImmuneCd3 Antigens

Grant awards (47)

Identification of Lethal Melanomas at the Time of Diagnosis$842,445
R01 · FY2024 · CA · contact PI
Identification of Lethal Melanomas at the Time of Diagnosis$888,702
R01 · FY2023 · CA · contact PI
Identification of Lethal Melanomas at the Time of Diagnosis$897,329
R01 · FY2022 · CA · contact PI
Integration of Clinical and Molecular Biomarkers for Melanoma Survival$598,220
P01 · FY2022 · CA
Integration of Clinical and Molecular Biomarkers for Melanoma Survival$1,987,168
P01 · FY2021 · CA
Identification of Lethal Melanomas at the Time of Diagnosis$918,430
R01 · FY2021 · CA · contact PI
Project 2: Primary melanoma DNA Methylation profiling for evaluating subtypes and survival$640,276
P01 · FY2021 · CA · contact PI
Integration of Clinical and Molecular Biomarkers for Melanoma Survival$112,686
P01 · FY2021 · CA
Identification of Lethal Melanomas at the Time of Diagnosis$972,565
R01 · FY2020 · CA · contact PI
Integration of Clinical and Molecular Biomarkers for Melanoma Survival$536,127
P01 · FY2020 · CA
Project 2: Primary melanoma DNA Methylation profiling for evaluating subtypes and survival$170,205
P01 · FY2020 · CA · contact PI
Sex Differences in Methylome Alterations and Mutational Burden in Early Stage Melanoma$95,969
P01 · FY2020 · CA
Project 2: Primary melanoma DNA Methylation profiling for evaluating subtypes and survival$11,996
P01 · FY2020 · CA · contact PI
Integration of Clinical and Molecular Biomarkers for Melanoma Survival$1,944,358
P01 · FY2019 · CA
Project 2: Primary melanoma DNA Methylation profiling for evaluating subtypes and survival$474,165
P01 · FY2019 · CA · contact PI
Integration of Clinical and Molecular Biomarkers for Melanoma Survival$74,384
P01 · FY2019 · CA
Project 2: Primary melanoma DNA Methylation profiling for evaluating subtypes and survival$9,299
P01 · FY2019 · CA · contact PI
Integration of Clinical and Molecular Biomarkers for Melanoma Survival$2,361,160
P01 · FY2018 · CA
Project 2: Primary melanoma DNA Methylation profiling for evaluating subtypes and survival$492,273
P01 · FY2018 · CA · contact PI
Genomic Evaluation of the Female Survival Advantages in Melanoma$75,897
P01 · FY2018 · CA
Integration of Clinical and Molecular Biomarkers for Melanoma Survival$2,292,665
P01 · FY2017 · CA
Project 2: Primary melanoma DNA Methylation profiling for evaluating subtypes and survival$510,217
P01 · FY2017 · CA · contact PI
TERT Promoter Mutation as a Melanoma Biomarker$76,000
R03 · FY2016 · CA · contact PI
TERT Promoter Mutation as a Melanoma Biomarker$76,000
R03 · FY2015 · CA · contact PI
Melanoma RAS/BRAF Mutation: Heterogeneity-Risk-Prognosis$479,355
R01 · FY2014 · CA · contact PI
Melanoma RAS/BRAF Mutation: Heterogeneity-Risk-Prognosis$467,820
R01 · FY2013 · CA · contact PI
High-Throughput DNA-Methylation Profiling from Fixed Melanocytic Tissues$312,242
R33 · FY2013 · CA · contact PI
Melanoma RAS/BRAF Mutation: Heterogeneity-Risk-Prognosis$511,659
R01 · FY2012 · CA · contact PI
High-Throughput DNA-Methylation Profiling from Fixed Melanocytic Tissues$330,935
R33 · FY2012 · CA · contact PI
Melanoma RAS/BRAF Mutation: Heterogeneity-Risk-Prognosis$529,369
R01 · FY2011 · CA · contact PI
High-Throughput DNA-Methylation Profiling from Fixed Melanocytic Tissues$335,977
R33 · FY2011 · CA · contact PI
Melanoma RAS/BRAF Mutation: Heterogeneity-Risk-Prognosis$586,568
R01 · FY2010 · CA · contact PI
DNA-Methylation Profiling from Fixed Melanocytic Tissues$161,932
R21 · FY2010 · CA · contact PI
Melanoma RAS/BRAF Mutation: Heterogeneity-Risk-Prognosis$498,844
R01 · FY2009 · CA · contact PI
Melanoma RAS/BRAF Mutation: Heterogeneity-Risk-Prognosis$287,571
R01 · FY2009 · CA · contact PI
DNA-Methylation Profiling from Fixed Melanocytic Tissues$194,329
R21 · FY2009 · CA · contact PI
Melanoma RAS/BRAF Mutation--Heterogeneity-Risk-Prognosis$495,393
R01 · FY2008 · CA · contact PI
Melanoma RAS/BRAF Mutation--Heterogeneity-Risk-Prognosis$498,851
R01 · FY2007 · CA · contact PI
Melanoma NRAS/BRAF Mutations: A Population-Based Study$130,058
K07 · FY2007 · CA · contact PI
Melanoma RAS/BRAF Mutation:Heterogeneity-Risk-Prognosis$504,784
R01 · FY2006 · CA · contact PI
Melanoma NRAS/BRAF Mutations: A Population-Based Study$130,058
K07 · FY2006 · CA · contact PI
Melanoma RAS/BRAF Mutation--Heterogeneity-Risk-Prognosis$559,031
R01 · FY2005 · CA
Melanoma NRAS/BRAF Mutations: A Population-Based Study$130,058
K07 · FY2005 · CA
Melanoma NRAS/BRAF Mutations: A Population-Based Study$130,058
K07 · FY2004 · CA
RAS/BRAF Melanoma Mutations: Precursors, Risk, Prognosis$73,000
R03 · FY2004 · CA
Melanoma NRAS/BRAF Mutations: A Population-Based Study$130,058
K07 · FY2003 · CA
RAS/BRAF Melanoma Mutations: Precursors, Risk, Prognosis$73,000
R03 · FY2003 · CA